Physician profile
Brett Sealove
NPI 1528239050
$409,500.46
in general payments reported to CMS, 2019-2025
27 companies · $90K in 2025
The $90K reported for 2025 was more than what 99% of Nuclear Cardiology providers received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105K · 2020: $33K · 2021: $24K · 2022: $17K · 2023: $58K · 2024: $83K · 2025: $90K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $90K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $62K · Consulting Fee: $37K · Travel and Lodging: $33K · Food and Beverage: $8,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,040.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $62,450.00 |
| Consulting Fee | $36,525.00 |
| Travel and Lodging | $32,999.03 |
| Food and Beverage | $8,416.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orapharma, A Division of Bausch Health US, LLC | $192,060.05 | 2022-2025 | Arestin |
| Janssen Pharmaceuticals, INC | $151,865.00 | 2019-2024 | Xarelto |
| Amgen INC. | $25,119.94 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $11,559.64 | 2021-2023 | Camzyos, Eliquis |
| Boston Scientific Corporation | $6,510.26 | 2019-2022 | |
| Bausch Health US, LLC | $4,700.00 | 2024-2025 | Aplenzin |
| Amarin Pharma, INC. | $3,892.86 | 2019 | |
| Abbott Laboratories | $3,632.54 | 2019-2025 | Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Idorsia Pharmaceuticals US INC | $3,540.00 | 2024 | Quviviq |
| Medtronic, INC. | $2,512.26 | 2023-2025 | Symplicity G3, Onyx Frontier, Apollotm |
| Janssen Scientific Affairs, LLC | $2,500.00 | 2020 | |
| Heartflow, INC. | $322.97 | 2025 | |
| Integra Lifesciences Corporation | $321.47 | 2022-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Abiomed | $146.30 | 2025 | |
| Smith+Nephew, INC. | $131.94 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $124.72 | 2022 | |
| Medtronic Vascular, INC. | $124.52 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.49 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $86.32 | 2019-2020 | |
| Pfizer INC. | $47.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $42.95 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $41.02 | 2020-2021 | |
| Cvrx, INC. | $35.41 | 2021 | |
| Cleerly, INC. | $28.04 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Siemens Medical Solutions USA, INC. | $19.03 | 2025 | Naeotom Alpha |
| Alexion Pharmaceuticals, INC. | $14.22 | 2021 | |
| Novo Nordisk INC | $13.65 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Sealove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.